Switch to:
More From Other Websites
IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 31 2014
IDENIX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2014 Financial Results Jul 31 2014
Merck, Pfizer Ramping R&D After Q2 Earnings Beat Jul 29 2014
Merck 2Q profit more than doubles Jul 29 2014
Hepatitis C researchers battle to 'nuke' the competition Jul 27 2014
Every Which Way But Short Jul 24 2014
[video] Cramer's Stop Trading: Yellen effect Jul 16 2014
A Pre-Earnings Update On Gilead Jul 10 2014
Seth Klarman Is Top-Performing Guru for First Half 2014 Jul 05 2014
A Primer On The Hepatitis C Market Jul 03 2014
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Jul 03 2014
Idenix (IDIX) is in Overbought Territory: What's Next? Jul 03 2014
What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck? Jun 27 2014
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly Jun 27 2014
Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains Jun 24 2014
Market Wrap For June 20: Yet Again, Dow And S&P 500 Indices Hit New Highs Jun 20 2014
[video] 3 Reasons for Russell 2000 surge Jun 20 2014
Achillion Could Win Idenix's Mystery Suitor: Analyst Jun 20 2014


Add Notes, Comments or Ask Questions

User Comments

Bradlewski
ReplyBradlewski - 3 weeks ago
Merck is buying it for $24.5/share.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide